Valuation: StimCell Energetics Inc.

Market Cap 58.35L 51.06L 47.17L 43.4L 81.8L 56Cr 83.65L 5.62Cr 2.21Cr 27Cr 2.19Cr 2.14Cr 95Cr P/E 2026 *
-6.9x
P/E 2027 * -13.8x
Enterprise Value 66.35L 58.06L 53.64L 49.35L 93.01L 64Cr 95.12L 6.39Cr 2.51Cr 31Cr 2.49Cr 2.44Cr 107.83Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
28.33%
Yield 2026 *
-
Yield 2027 * -
1 day-12.10%
Current month-12.10%
1 month-21.14%
3 months-8.00%
6 months-40.17%
Current year-31.00%
1 month 0.28
Extreme 0.276
0.35
Current year 0.28
Extreme 0.276
0.48
1 year 0.25
Extreme 0.2501
0.48
3 years 0
Extreme 0.0015
13.97
5 years 0
Extreme 0
13.97
10 years 0
Extreme 0
25.35
Manager TitleAgeSince
Chief Executive Officer 56 12/12/2023
Director of Finance/CFO 48 24/11/2014
Director TitleAgeSince
Director/Board Member 56 12/12/2023
Director/Board Member 62 08/06/2020
Chairman 78 26/02/2024
Date Insider Type Main position Quantity % Market Cap.
18/12/25 Sell

Director

16,667 0.0807%
17/03/25 Tax

Director

6,08,41,472 307.0278%
25/02/25 Buy 15,000 0.0757%
Change 5-day change 1-year change 3-year change Capi.($)
-12.10%0.00%+2.22%-8.00% 58.35L
-1.29%-3.11%-0.35%+3.09% 4.92TCr
+3.90%-0.39%+386.06%+593.85% 3.96TCr
-1.70%+4.46%+5.93%+60.25% 3.47TCr
-2.01%-0.76%+28.41%-8.01% 3.44TCr
+0.06%+0.34%+2.38%+34.38% 2.71TCr
+0.46%-3.49% - - 1.62TCr
-0.04%-0.09%+72.42%+115.55% 1.54TCr
+1.12%+1.91%+14.54%+19.16% 1.41TCr
0.00%+1.36%+18.43%-30.79% 1.3TCr
Average -1.16%+0.02%+58.89%+86.61% 2.44TCr
Weighted average by Cap. -0.05%-0.18%+79.44%+123.31%

Financials

2026 *2027 *
Net sales - -
Net income -79Cr -69Cr -64Cr -59Cr -111.08Cr -7.63TCr -113.59Cr -763.59Cr -300.34Cr -3.73TCr -297.56Cr -291.02Cr -13TCr -51Cr -45Cr -41Cr -38Cr -71Cr -4.91TCr -73Cr -491.45Cr -193.31Cr -2.4TCr -191.52Cr -187.3Cr -8.29TCr
Net Debt 8L 7L 6L 6L 11.21L 7.7Cr 11.47L 77.09L 30.32L 3.77Cr 30.04L 29.38L 13Cr 8L 7L 6L 6L 11.21L 7.7Cr 11.47L 77.09L 30.32L 3.77Cr 30.04L 29.38L 13Cr
Logo StimCell Energetics Inc.
StimCell Energetics Inc. is a biotech company, which is focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that enhance cellular function, promote general wellness and alleviate health complications including, but not limited to aging, insulin sensitivity, high blood pressure, neuropathy and kidney function. The Company's main focus is on continued research and development of its eBalance Technology and its eBalance Home System. eBalance is a non-invasive, fully automated microcurrent electrotherapy system administering pre-programmed algorithms through the epidermis at the touch of a button to help you gain optimal wellness and reduce pain. Its eBalance represents a monumental stride in the realm of medical technology designed to rejuvenate and re-energize the human body at a cellular level. The operation of eBalance is an intricate process of precision engineering and human biology.
Employees
1
Date Price Change Volume

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STME Stock